Adam Hansard

Adam Hansard joined Applied Therapeutics as Chief Commercial Officer in March 2020. Prior to joining Applied Therapeutics, Mr. Hansard was at Alexion Pharmaceuticals, where he led a company-wide business unit team, ran the ALXN1830 commercial team, and was responsible for commercial evaluation of strategic business development opportunities. Previously, he was Vice President of Business Operations at Syntimmune, a clinical-stage biotech purchased by Alexion in Nov. 2018. At Syntimmune, he was responsible for all commercial areas, including strategy, marketing, communications, forecasting, and was also a core member of the Executive Leadership Team. Prior to Syntimmune, Mr. Hansard held various positions at Sanofi and Sanofi Genzyme, including sales, marketing, training, communications and commercial leadership. As Chief of Staff for Sanofi Genzyme Multiple Sclerosis, Immunology and Oncology North America, he was a key contributor in the creation of the Dermatology and Rheumatology Business Units.